JP2018508548A - 膀胱機能を改善する方法 - Google Patents
膀胱機能を改善する方法 Download PDFInfo
- Publication number
- JP2018508548A JP2018508548A JP2017549049A JP2017549049A JP2018508548A JP 2018508548 A JP2018508548 A JP 2018508548A JP 2017549049 A JP2017549049 A JP 2017549049A JP 2017549049 A JP2017549049 A JP 2017549049A JP 2018508548 A JP2018508548 A JP 2018508548A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- vitamin
- bladder
- uridine
- pufa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims abstract description 64
- 208000020431 spinal cord injury Diseases 0.000 claims abstract description 38
- 229940045145 uridine Drugs 0.000 claims abstract description 31
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims abstract description 30
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 130
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 45
- 229960001231 choline Drugs 0.000 claims description 38
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 38
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 36
- 239000007788 liquid Substances 0.000 claims description 33
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 30
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 29
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 claims description 25
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical group O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 claims description 25
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 24
- 235000019152 folic acid Nutrition 0.000 claims description 20
- 239000011724 folic acid Substances 0.000 claims description 20
- 150000003904 phospholipids Chemical class 0.000 claims description 20
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 20
- 235000019158 vitamin B6 Nutrition 0.000 claims description 20
- 239000011726 vitamin B6 Substances 0.000 claims description 20
- 229940067631 phospholipid Drugs 0.000 claims description 19
- 229940011671 vitamin b6 Drugs 0.000 claims description 19
- 229930003270 Vitamin B Natural products 0.000 claims description 18
- 235000019156 vitamin B Nutrition 0.000 claims description 18
- 239000011720 vitamin B Substances 0.000 claims description 18
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 17
- 229960000304 folic acid Drugs 0.000 claims description 17
- 239000003963 antioxidant agent Substances 0.000 claims description 16
- 235000006708 antioxidants Nutrition 0.000 claims description 16
- 238000011084 recovery Methods 0.000 claims description 16
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 15
- 235000019163 vitamin B12 Nutrition 0.000 claims description 15
- 239000011715 vitamin B12 Substances 0.000 claims description 15
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 14
- 229930003779 Vitamin B12 Natural products 0.000 claims description 14
- 239000011669 selenium Substances 0.000 claims description 14
- 229910052711 selenium Inorganic materials 0.000 claims description 14
- 235000011649 selenium Nutrition 0.000 claims description 14
- 235000019165 vitamin E Nutrition 0.000 claims description 14
- 239000011709 vitamin E Substances 0.000 claims description 14
- 229930003427 Vitamin E Natural products 0.000 claims description 13
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 13
- 235000019154 vitamin C Nutrition 0.000 claims description 13
- 239000011718 vitamin C Substances 0.000 claims description 13
- 229940046009 vitamin E Drugs 0.000 claims description 13
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 12
- 229930003268 Vitamin C Natural products 0.000 claims description 12
- 208000012902 Nervous system disease Diseases 0.000 claims description 10
- 230000003078 antioxidant effect Effects 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 9
- 210000003932 urinary bladder Anatomy 0.000 description 71
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 42
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 40
- 230000006870 function Effects 0.000 description 34
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 28
- 239000000047 product Substances 0.000 description 22
- 241000700159 Rattus Species 0.000 description 16
- 230000027939 micturition Effects 0.000 description 16
- 230000006378 damage Effects 0.000 description 15
- 206010069632 Bladder dysfunction Diseases 0.000 description 14
- 235000005911 diet Nutrition 0.000 description 13
- 208000014674 injury Diseases 0.000 description 13
- 210000005070 sphincter Anatomy 0.000 description 13
- 208000027418 Wounds and injury Diseases 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 11
- 229930195729 fatty acid Natural products 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- 150000004665 fatty acids Chemical class 0.000 description 11
- 235000016709 nutrition Nutrition 0.000 description 11
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 210000005036 nerve Anatomy 0.000 description 9
- 235000019159 vitamin B9 Nutrition 0.000 description 9
- 239000011727 vitamin B9 Substances 0.000 description 9
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 8
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 8
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 8
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 8
- 206010029279 Neurogenic bladder Diseases 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 208000030886 Traumatic Brain injury Diseases 0.000 description 7
- 229930003761 Vitamin B9 Natural products 0.000 description 7
- 230000011514 reflex Effects 0.000 description 7
- 230000009529 traumatic brain injury Effects 0.000 description 7
- 230000002485 urinary effect Effects 0.000 description 7
- 201000001119 neuropathy Diseases 0.000 description 6
- 230000007823 neuropathy Effects 0.000 description 6
- 208000033808 peripheral neuropathy Diseases 0.000 description 6
- -1 sachets Substances 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 5
- 208000010886 Peripheral nerve injury Diseases 0.000 description 5
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 5
- XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 description 5
- 208000029028 brain injury Diseases 0.000 description 5
- 230000004064 dysfunction Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 235000020778 linoleic acid Nutrition 0.000 description 5
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 5
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 210000000278 spinal cord Anatomy 0.000 description 5
- 206010046494 urge incontinence Diseases 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 206010056948 Automatic bladder Diseases 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 208000024449 overflow incontinence Diseases 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229930003799 tocopherol Natural products 0.000 description 4
- 239000011732 tocopherol Substances 0.000 description 4
- 229960001295 tocopherol Drugs 0.000 description 4
- 235000010384 tocopherol Nutrition 0.000 description 4
- 230000000472 traumatic effect Effects 0.000 description 4
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 206010021639 Incontinence Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 3
- 206010046555 Urinary retention Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229940087168 alpha tocopherol Drugs 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 229940014144 folate Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000008447 perception Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- 229950010342 uridine triphosphate Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 235000004835 α-tocopherol Nutrition 0.000 description 3
- 239000002076 α-tocopherol Substances 0.000 description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 2
- ZLNQYWQOOXQPMZ-FWHJPCMOSA-N 3-[(4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-pyrimidine-2,4-dione Chemical compound C1(C[C@H](O)[C@H](O1)CO)N1C(NC=CC1=O)=O ZLNQYWQOOXQPMZ-FWHJPCMOSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 206010020853 Hypertonic bladder Diseases 0.000 description 2
- 208000010495 Meningocele Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010033892 Paraplegia Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 206010037714 Quadriplegia Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 201000010829 Spina bifida Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 206010008129 cerebral palsy Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000012263 liquid product Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 150000003906 phosphoinositides Chemical class 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 150000003248 quinolines Chemical class 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 description 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-FWHJPCMOSA-N 4-amino-1-[(4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1C1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-FWHJPCMOSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- SGFBLYBOTWZDDE-UHFFFAOYSA-N Choline stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC[N+](C)(C)C SGFBLYBOTWZDDE-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010067633 Peripheral nerve lesion Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
- 206010049679 Spinal shock Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- 229960001849 choline stearate Drugs 0.000 description 1
- 229960001284 citicoline Drugs 0.000 description 1
- 229940010007 cobalamins Drugs 0.000 description 1
- 150000001867 cobalamins Chemical class 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000020979 dietary recommendations Nutrition 0.000 description 1
- 235000020930 dietary requirements Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000002307 glutamic acids Chemical class 0.000 description 1
- RBNPOMFGQQGHHO-UHFFFAOYSA-N glyceric acid Chemical compound OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000036453 micturition reflex Effects 0.000 description 1
- 201000010193 neural tube defect Diseases 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000003018 neuroregenerative effect Effects 0.000 description 1
- 208000002040 neurosyphilis Diseases 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 238000011903 nutritional therapy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 238000009803 radical hysterectomy Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 201000006361 tethered spinal cord syndrome Diseases 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000021470 vitamin B5 (pantothenic acid) Nutrition 0.000 description 1
- 235000021467 vitamin B7(Biotin) Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
組成物
本発明による方法もしくは使用または使用のための組成物は、本発明による組成物を投与することを含む。本発明による組成物は、医薬製品または栄養製品として使用されてもよい。
ウリジン
本発明の組成物は、(i)ウリジンおよび/またはその等価物を含む。ウリジン等価物は当技術分野において既知であり、ウリジン等価物としては、典型的には、デオキシウリジン(デオキシリボシルウラシル)、ウリジンリン酸(UMP、dUMP、UDP、UTP)、核酸塩基ウラシル、アシル化ウリジン誘導体(たとえば、C1〜6アシル化ウリジン)、および/またはエステル(たとえば、C1〜6アルカン酸エステル)がある。組成物は、好ましくは、ウリジン(リボシルウラシル)、デオキシウリジン(デオキシリボシルウラシル)、ウリジンリン酸(UMP、dUMP、UDP、UTP)、核酸塩基ウラシル、アシル化ウリジン誘導体、およびこれらの混合物から選択される成分(i)、より好ましくは、ウリジン一リン酸(UMP)、ウリジン二リン酸(UDP)、およびウリジン三リン酸(UTP)から選択されるウリジンリン酸を含む。UMPは最も効率的に体内に取り込まれるため、最も好ましくは、組成物はUMPを含む。したがって、本発明の組成物においてUMPを含むことによって、低投与量での高い有効性および/または低用量での対象への投与が可能になる。
シチジン
組成物はまた、ウリジンに加えてまたはその代わりに、シチジンおよび/またはその等価物を含んでいてもよい。シチジン等価物は当技術分野において既知であり、シチジン等価物としては、典型的には、デオキシシチジン(デオキシリボシルシトシン)、シチジンリン酸(UMP、dUMP、UDP、UTP)、核酸塩基シトシン、アシル化シチジン誘導体(たとえば、C1〜6アシル化シチジン)および/またはエステル(たとえば、C1〜6アルカン酸エステル)がある。1つの態様において、シチジン、シチジンリン酸(CMP、CDP、CTP、好ましくはCMP)、シチコリン(CDP−コリン)から選択される1つ以上を含む組成物がまた適用されていてもよい。
n−3PUFA
本組成物は、(ii)n−3多価不飽和脂肪酸(PUFA)、好ましくはn−3LC−PUFAを含む。本発明に関して、LC−PUFA(長鎖PUFA)は、炭素原子18個以上の鎖長を有する。
さらなる脂質成分
n−3PUFAに次いで、組成物は、好ましくは、さらなる脂質、たとえば、n−6PUFAまたはn−6LC−PUFA(たとえば、α−リノレン酸(ALA)、リノール酸(LA))およびリン脂質を含む。
さらなる成分
本発明による組成物は、さらなる成分、たとえば、コリンおよび(1種以上の)ビタミンBから選択される1つ以上、好ましくはその両方、より好ましくはさらに抗酸化剤を含んでいてもよい。脊髄損傷は、これらの成分の栄養欠乏をもたらすことが示唆された(Fraser 2014)ため、コリン、(1種以上の)ビタミンB、特に葉酸およびビタミンB6、ならびに抗酸化剤、特にビタミンCおよび/またはEのうちの1つ以上、好ましくはすべてが存在することが好ましい。したがって、コリン、(1種以上の)ビタミンB、特にビタミンB12、ならびに抗酸化剤、特にセレン、ビタミンCおよび/またはEの存在は、脊髄損傷を患う患者の総体的な健康に寄与し得る。
コリン
本発明の組成物は、好ましくはコリンを含む。コリンは、そのまま、または、たとえば、塩もしくはエステル型、またはこれらの任意の組み合わせの形態でコリン等価物として存在していてもよい。コリン塩は、好ましくは、塩化コリン、酒石酸水素コリン、またはステアリン酸コリンから選択される。コリンエステルは、好ましくは、ホスファチジルコリンおよびリゾホスファチジルコリンから選択される。
ビタミンB群
本発明の組成物は、1種以上のビタミンBをさらに含んでいてもよい。ビタミンBは、ビタミンB1(チアミン)、ビタミンB2(リボフラビン)、ビタミンB3(ナイアシンまたはナイアシンアミド)、ビタミンB5(パントテン酸)、ビタミンB6(ピリドキシン、ピリドキサール、もしくはピリドキサミン、またはピリドキシン塩酸塩)、ビタミンB7(ビオチン)、ビタミンB9(葉酸またはフォレート)、およびビタミンB12(種々のコバラミン)の群から選択される。機能的等価物は、これらの用語に包含される。「ビタミンB12」という用語は、当技術分野において既知のすべてのコバラミン等価物を包含する。好ましくは、本発明に関するビタミンBは、ビタミンB6、ビタミンB12、およびビタミンB9の群から選択される少なくとも1種、より好ましくは少なくとも2種を含む。より好ましくは、組成物は、少なくともビタミンB6および/またはB9、最も好ましくはビタミンB6、B9、およびB12を含む。
抗酸化剤
本発明の組成物は、好ましくはビタミンC、ビタミンE、およびセレンから選択される抗酸化剤をさらに含んでいてもよい。組成物は、ビタミンCとビタミンEの両方を含むことが特に好ましく、最も好ましくは本発明による組成物は、ビタミンC、ビタミンE、およびセレンを含む。抗酸化剤は、食事由来のPUFAから生じる損傷部位に対する酸化的傷害を予防し得るため、好ましくは、本発明による組成物中に含まれる。
(i)400〜1000mg、好ましくは500〜700mg、より好ましくは約625mgのUMP、
(ii−a)100〜500mg、好ましくは200〜400mg、より好ましくは約300mgのEPA、
(ii−b)900〜2000mg、好ましくは950〜1300mg、より好ましくは約1200mgのDHA、
(iii)50〜600mg、好ましくは60〜200mg、より好ましくは約106mgのリン脂質、
(iv)200〜800mg、好ましくは300〜500mg、より好ましくは約400mgのコリン、
(v−a)1〜5μg、好ましくは2〜4μg、より好ましくは約3μgのビタミンB12、
(v−b)0.5〜3mg、好ましくは0.5〜2mg、より好ましくは約1mgのビタミンB6、
(v−c)200〜800μg、好ましくは300〜500μg、より好ましくは約400μgの葉酸
(vi−a)20〜80mg、好ましくは30〜50mg、より好ましくは約40mgのビタミンE(α−トコフェロール等価物(α−TE))、
(vi−b)60〜150mg、好ましくは60〜90mg、より好ましくは約80mgのビタミンC、および
(vi−c)40〜100μg、好ましくは45〜65μg、より好ましくは約60μgのセレン
を含む。
(i)600〜1500mg、好ましくは700〜1050mg、より好ましくは約940mgのUMP、
(ii−a)150〜750mg、好ましくは320〜600mg、より好ましくは約450mgのEPA、
(ii−b)1000〜3000mg、好ましくは1400〜2000mg、より好ましくは約1800mgのDHA、
(iii)75〜900mg、好ましくは110〜300mg、より好ましくは約160mgのリン脂質、
(iv)300〜120mg、好ましくは450〜750mg、より好ましくは約600mgのコリン、
(v−a)1.5〜7.5μg、好ましくは4〜6μg、より好ましくは約4.5μgのビタミンB12、
(v−b)0.75〜4.5mg、好ましくは1.2〜3mg、より好ましくは約1.5mgのビタミンB6、
(v−c)300〜1200μg、好ましくは450〜750μg、より好ましくは約600μgの葉酸、
(vi−a)30〜120mg、好ましくは45〜75mg、より好ましくは約60mgのビタミンE(α−トコフェロール等価物(alpha−TE))、
(vi−b)70〜225mg、好ましくは90〜135mg、より好ましくは約120mgのビタミンC、および
(vi−c)50〜150μg、好ましくは65〜100μg、より好ましくは約80μgのセレン
を含む。
適用
本発明による組成物は、対象において、膀胱機能(障害)を回復させるか、もしくは改善するためのもの、または膀胱機能の回復を改善するためのものである。本発明の使用はまた、膀胱機能または膀胱制御(の回復を)の刺激、膀胱機能または膀胱制御の回復の改善、自律膀胱機能の改善、尿失禁の治療および/または予防、尿漏れ(leaky bladder)の治療および/または予防と表現してもよい。本発明に関して、「予防」はまた、「リスクまたは発症の減少」と呼んでもよい。本発明に関して、膀胱機能障害は、任意の形態、たとえば、失禁(たとえば、切迫性失禁、溢流性失禁)、痙性膀胱、閉尿、低収縮性膀胱、頻尿、夜間頻尿、過活動膀胱、(充満した)膀胱知覚の低下または消失、排尿後の残尿感の増加であってもよい。
例1
雌成体Sprague−Dawleyラット(約250g)をこの研究で使用した。すべての動物の脊髄を胸郭レベルT12(T12)で損傷させた、静的圧迫モデルを使用した(Nystrom et al.,Acta Neurologica Scandinavica,1998,78,460−6;Huang et al.,European Journal of Neuroscience,2007,23,273−8)。手術後、ラットを、全ての有害反応に関して定期的にモニターし、損傷させてから最初の2週間は毎日秤量し、次いでその後は週に2回秤量した。手術してから最初の1週間は、膀胱を1日2回チェックし、必要であれば手動で絞り出し、次いでその後は、排尿反射が回復するまで1日1回チェックした。
本発明による液体組成物は、1回分125ml当たり:
以下に、出願当初の請求項を実施の態様として付記する。
[1] 対象における膀胱機能を回復させるか、または改善する方法であって、(i)ウリジンおよび/またはその等価物、ならびに(ii)n−3PUFAを含む組成物を前記対象に投与することを含む、方法。
[2] 前記対象が、神経障害、好ましくは脊髄損傷を患う患者、その回復期にある患者、および/またはそれを患っていた患者である、[1]に記載の方法。
[3] 前記n−3PUFAが、EPAおよび/またはDHAから選択される、[1]または[2]に記載の方法。
[4] 1日当たり500〜5000mgのDHAを投与する、先行する請求項の何れか1項に記載の方法。
[5] 前記組成物が、コリンをさらに含み、好ましくは(1種以上の)ビタミンBをさらに含む、先行する請求項の何れか1項に記載の方法。
[6] 前記組成物が、リン脂質、コリン、(1種以上の)ビタミンB、および抗酸化剤をさらに含む、先行する請求項の何れか1項に記載の方法。
[7] 前記組成物が、コリン、ビタミンB6、および葉酸を含む、[5]または[6]に記載の方法。
[8] 前記ウリジンおよび/またはその等価物がウリジン一リン酸である、先行する請求項の何れか1項に記載の方法。
[9] 前記組成物が、125ml当たりまたは1日投与量当たり、
(i)400〜800mgのUMP、
(ii)(a)100〜500mgのEPAおよび(b)900〜1500mgのDHAを含むn−3PUFA、
(iii)50〜600mgのリン脂質、
(iv)200〜600mgのコリン、
(v)(a)1〜5μgのビタミンB12、(b)0.5〜3mgのビタミンB6、および(c)200〜600μgの葉酸を含むビタミンB、ならびに
(vi)(a)20〜60mgのビタミンE(α−TE)、(b)60〜100mgのビタミンC、および(c)40〜80μgのセレンを含む抗酸化剤
を含む、先行する請求項の何れか1項に記載の方法。
[10] 前記組成物が、液体、または液体で溶解可能な固形物である、先行する請求項の何れか1項に記載の方法。
[11] 対象における膀胱機能の回復または改善に使用するための組成物であって、(i)ウリジンおよび/またはその等価物、ならびに(ii)n−3PUFAを含む、組成物。
[12] 対象における膀胱機能を回復させるか、または改善するための組成物を製造するための(i)ウリジンおよび/またはその等価物、ならびに(ii)n−3PUFAの使用。
[13] 前記対象が、神経障害、好ましくは脊髄損傷を患う患者、その回復期にある患者、および/またはそれを患っていた患者である、[11]に記載の使用のための組成物または[12]に記載の使用。
Claims (13)
- 対象における膀胱機能を回復させるか、または改善する方法であって、(i)ウリジンおよび/またはその等価物、ならびに(ii)n−3PUFAを含む組成物を前記対象に投与することを含む、方法。
- 前記対象が、神経障害、好ましくは脊髄損傷を患う患者、その回復期にある患者、および/またはそれを患っていた患者である、請求項1に記載の方法。
- 前記n−3PUFAが、EPAおよび/またはDHAから選択される、請求項1または2に記載の方法。
- 1日当たり500〜5000mgのDHAを投与する、先行する請求項の何れか1項に記載の方法。
- 前記組成物が、コリンをさらに含み、好ましくは(1種以上の)ビタミンBをさらに含む、先行する請求項の何れか1項に記載の方法。
- 前記組成物が、リン脂質、コリン、(1種以上の)ビタミンB、および抗酸化剤をさらに含む、先行する請求項の何れか1項に記載の方法。
- 前記組成物が、コリン、ビタミンB6、および葉酸を含む、請求項5または6に記載の方法。
- 前記ウリジンおよび/またはその等価物がウリジン一リン酸である、先行する請求項の何れか1項に記載の方法。
- 前記組成物が、125ml当たりまたは1日投与量当たり、
(i)400〜800mgのUMP、
(ii)(a)100〜500mgのEPAおよび(b)900〜1500mgのDHAを含むn−3PUFA、
(iii)50〜600mgのリン脂質、
(iv)200〜600mgのコリン、
(v)(a)1〜5μgのビタミンB12、(b)0.5〜3mgのビタミンB6、および(c)200〜600μgの葉酸を含むビタミンB、ならびに
(vi)(a)20〜60mgのビタミンE(α−TE)、(b)60〜100mgのビタミンC、および(c)40〜80μgのセレンを含む抗酸化剤
を含む、先行する請求項の何れか1項に記載の方法。 - 前記組成物が、液体、または液体で溶解可能な固形物である、先行する請求項の何れか1項に記載の方法。
- 対象における膀胱機能の回復または改善に使用するための組成物であって、(i)ウリジンおよび/またはその等価物、ならびに(ii)n−3PUFAを含む、組成物。
- 対象における膀胱機能を回復させるか、または改善するための組成物を製造するための(i)ウリジンおよび/またはその等価物、ならびに(ii)n−3PUFAの使用。
- 前記対象が、神経障害、好ましくは脊髄損傷を患う患者、その回復期にある患者、および/またはそれを患っていた患者である、請求項11に記載の使用のための組成物または請求項12に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/NL2015/050168 WO2016148561A1 (en) | 2015-03-16 | 2015-03-16 | Method for improving bladder function |
NLPCT/NL2015/050168 | 2015-03-16 | ||
PCT/NL2016/050184 WO2016148568A1 (en) | 2015-03-16 | 2016-03-15 | Method for improving bladder function |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2018508548A true JP2018508548A (ja) | 2018-03-29 |
Family
ID=52829270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017549049A Pending JP2018508548A (ja) | 2015-03-16 | 2016-03-15 | 膀胱機能を改善する方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20180110794A1 (ja) |
EP (1) | EP3270905A1 (ja) |
JP (1) | JP2018508548A (ja) |
KR (1) | KR20170138434A (ja) |
CN (1) | CN107635551A (ja) |
AU (1) | AU2016233980A1 (ja) |
BR (1) | BR112017019838A2 (ja) |
CA (1) | CA2979979A1 (ja) |
MX (1) | MX2017011994A (ja) |
RU (1) | RU2715247C2 (ja) |
SG (1) | SG11201707591YA (ja) |
WO (2) | WO2016148561A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014511830A (ja) * | 2011-03-14 | 2014-05-19 | エヌ.ブイ.・ヌートリシア | 神経外傷を治療するための方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US30853A (en) * | 1860-12-04 | Machine fob | ||
US8518882B2 (en) | 1998-07-31 | 2013-08-27 | Massachusetts Institute Of Technology | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
WO2009002145A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Lipid composition for improving function of brain functioning |
WO2013066152A1 (en) | 2011-10-31 | 2013-05-10 | N.V. Nutricia | Method for improving executive function |
WO2013066151A1 (en) | 2011-10-31 | 2013-05-10 | N.V. Nutricia | Improving recognition |
-
2015
- 2015-03-16 WO PCT/NL2015/050168 patent/WO2016148561A1/en active Application Filing
-
2016
- 2016-03-15 EP EP16718513.1A patent/EP3270905A1/en not_active Withdrawn
- 2016-03-15 AU AU2016233980A patent/AU2016233980A1/en not_active Abandoned
- 2016-03-15 SG SG11201707591YA patent/SG11201707591YA/en unknown
- 2016-03-15 WO PCT/NL2016/050184 patent/WO2016148568A1/en active Application Filing
- 2016-03-15 CA CA2979979A patent/CA2979979A1/en not_active Abandoned
- 2016-03-15 JP JP2017549049A patent/JP2018508548A/ja active Pending
- 2016-03-15 KR KR1020177029741A patent/KR20170138434A/ko unknown
- 2016-03-15 RU RU2017134335A patent/RU2715247C2/ru not_active IP Right Cessation
- 2016-03-15 US US15/558,702 patent/US20180110794A1/en not_active Abandoned
- 2016-03-15 MX MX2017011994A patent/MX2017011994A/es unknown
- 2016-03-15 BR BR112017019838A patent/BR112017019838A2/pt not_active Application Discontinuation
- 2016-03-15 CN CN201680028041.9A patent/CN107635551A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014511830A (ja) * | 2011-03-14 | 2014-05-19 | エヌ.ブイ.・ヌートリシア | 神経外傷を治療するための方法 |
Non-Patent Citations (3)
Title |
---|
FIGUEROA J D; CORDERO K; LLN M S; ET AL: "DIETARY OMEGA-3 POLYUNSATURATED FATTY ACIDS IMPROVE THE NEUROLIPIDOME AND RESTORE THE DHA 以下備考", JOURNAL OF NEUROTRAUMA, vol. VOL:30, NR:10, JPN5018000951, 15 May 2013 (2013-05-15), pages 853 - 868, ISSN: 0004268612 * |
YU W; SUN X; ROBSON S C; ET AL: "EXTRACELLULAR UDP ENHANCES P2X-MEDIATED BLADDER SMOOTH MUSCLE CONTRACTILITY VIA P2Y(6) 以下備考", THE FASEB JOURNAL, vol. VOL:27, NR:5, JPN5018000952, May 2013 (2013-05-01), pages 1895 - 1903, ISSN: 0004268613 * |
医学のあゆみ, vol. 238(4), JPN6019051259, 2011, pages 317 - 323, ISSN: 0004184122 * |
Also Published As
Publication number | Publication date |
---|---|
EP3270905A1 (en) | 2018-01-24 |
AU2016233980A1 (en) | 2017-10-19 |
SG11201707591YA (en) | 2017-10-30 |
RU2017134335A3 (ja) | 2019-09-18 |
CN107635551A (zh) | 2018-01-26 |
RU2017134335A (ru) | 2019-04-03 |
KR20170138434A (ko) | 2017-12-15 |
CA2979979A1 (en) | 2016-09-22 |
WO2016148568A1 (en) | 2016-09-22 |
RU2715247C2 (ru) | 2020-02-26 |
WO2016148561A1 (en) | 2016-09-22 |
BR112017019838A2 (pt) | 2018-06-05 |
US20180110794A1 (en) | 2018-04-26 |
MX2017011994A (es) | 2018-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10071072B2 (en) | Method for treating neurotrauma | |
JP5841723B2 (ja) | ミニメンタルステート検査24〜26点の被験者における記憶力改善 | |
EP3099327A1 (en) | Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly | |
US11141397B2 (en) | Composition for improving efficacy of L-DOPA treatment | |
JP2018508548A (ja) | 膀胱機能を改善する方法 | |
EP3468543B1 (en) | Method for controlling neuroinflammation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171116 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190313 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200407 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200526 |